Assessment of laboratory measures to determine safety includes review for new-onset abnormalities (confirmed with repeat testing at the following clinical visit or as soon as possible following closeout, as applicable), including new-onset clinically significant elevation of liver function tests [aspartate transaminase (AST), alanine transaminase (ALT), bilirubin or alkaline phosphatase], new-onset anemia, elevations in creatinine, and/or reductions in estimated glomerular filtration rate (eGFR). This evidence concerns the gene GPT and anemia.